Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Capecitabine + Docetaxel vs Sequential Capecitabine then Docetaxel in MBC
NCT00087620Phase 4Terminated
- Sponsor
- Roche
- Start
- Sep 2004
- Primary completion
- Oct 2004
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of capecitabine in breast cancer (2 arms), sponsored by Roche. Primary endpoint: Time to Progression. Started Sep 2004; status: terminated.
02
Drugs
capecitabine
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00087620.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00087620.